R&D channel feed – Endpoints News

R&D channel feed

US supports extension for Covid-19 IP waiver decision

3 years ago

Editas reports early-stage data from two patients in sickle cell disease

3 years ago

AbbVie puts up $40M to license a treatment from HotSpot Therapeutics

3 years ago

Compugen touts ovarian cancer data in combo with Opdivo, anti-TIGIT from ex-partner Bristol Myers

3 years ago

As FDA door shuts on its PI3K, MEI Pharma throws in the towel, lays off staff

3 years ago

Gossamer’s Faheem Hasnain defends a round of positive PAH data as a clear win. But can these PhII results stand up to scrutiny?

3 years ago

Nkarta underscores safety of CAR-NK, boasts early responses

3 years ago

Pfizer-backed Mediar Therapeutics ropes in another Big Pharma investor

3 years ago

Verve reveals letter from FDA that lays out conditions to lift base editing trial hold

3 years ago

Valneva's chikungunya vaccine on track for FDA nod after long-term antibody data

3 years ago

Amgen, years behind rivals, says PhI obesity drug shows durability signs

3 years ago

Salarius Pharmaceuticals sees withdrawals, 3 of 13 patient responders in sarcoma trial

3 years ago

FDA rejects Y-mAbs’ neuroblastoma drug after taking issue with clinical trial design

3 years ago

Pfizer backs $60M infusion into Carrick, teams up on breast cancer treatment

3 years ago

Pfizer and Roivant team up again for another 'Vant', setting up anti-inflammatory showdown with Prometheus

3 years ago

As competitors near FDA goalpost, Roche spells out its repeat Alzheimer's setback

3 years ago

As money pours into digital therapeutics, insurance coverage crawls

3 years ago

SQZ Biotech slashes headcount by 60% as founder/CEO hits exit — while Synlogic lays off 25%

3 years ago

Rallybio, AbCellera form new partnership around antibodies for rare disease

3 years ago

Eli Lilly’s Alzheimer’s drug clears more amyloid early than Aduhelm in first-ever head-to-head. Will it matter?

3 years ago

Sanofi and DNDi aim to eliminate sleeping sickness in Africa with promising Ph II/III results for new drug

3 years ago

Protecting its megablockbuster, Janssen challenges Amgen's Stelara biosimilar ahead of planned 2023 launch

3 years ago

In cash saving mode, Oncorus cuts trial, staff, lease, and pipeline

3 years ago

X4 Pharmaceuticals pulls together some positive data results after a rocky year

3 years ago

First page Previous page 108 109 110111112 113 114 Next page Last page